OR WAIT null SECS
ProBioGen will facilitate the development of Immunogenesis’ monoclonal antibody candidate and will be responsible for manufacturing the drug at its new facility in Berlin, Germany.
ProBioGen, a Berlin, Germany-based development and manufacturing specialist, and Immunogenesis, a spin-off of the MD Anderson Cancer Center, announced on March 24, 2020 that they have signed a service agreement for cell-line development, process development, and GMP manufacturing at 1000-L bioreactor scale for Immunogenesis’ lead immuno-oncology candidate, a monoclonal antibody (mAb).
According to a ProBioGen press release, ProBioGen will facilitate the development and of the mAb candidate at its new facility in Berlin.
“We are very excited to enter the development and manufacturing phase with our lead candidate”, said Michael A. Curran, founder of Immunogenesis and associate professor at the MD Anderson Cancer Center, in the press release. “And with ProBioGen we found the right partner that has great scientific expertise and the ‘can-do’ mindset, which we very much appreciate for this challenging step.”
“It is great to be part of the transition of the molecule to the clinic, and we are looking forward working together with Immunogenesis on the realization of their project,” added Dr. Wieland Wolf, CEO of ProBioGen, in the press release.